RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
← catalyst calendarSponsored by Altimmune, Inc. (industry) · ALT — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100actual
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-15 | actual | When the study began enrolling |
| Primary completion | 2026-07-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-30 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alcohol Use Disorder (AUD)
Interventions
- Drug: Pemvidutide
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in the average number of heavy drinking days per week
measured Baseline to Weeks 21-24
Permalink · ALT's whole pipeline · Catalyst calendar · Every registered study · What changed